BioCentury | Oct 25, 2018
Distillery Therapeutics

Infectious disease

...INDICATION: Bacterial infection In vitro and cell culture studies identified kanglemycin-based RNAP inhibitors that could help...
...to > 50 μg/mL). In vitro , the compounds decreased transcription mediated by Mycobacterium smegmatis RNAP...
...Next steps could include testing the compounds in animal models of rifamycin-resistant bacterial infections. TARGET/MARKER/PATHWAY: Bacterial RNA polymerase (RNAP)...
BioCentury | Jun 19, 2017
Clinical News

Antibiotic derived from soil could address drug resistance

...directly with uridine triphosphate for binding to RNAP. The compound showed no cross-resistance with other RNAP-targeting...
...RNAP, due to a sidechain that binds to an adjacent site present only in bacterial RNAP...
...inhibitor linked to a salinamide, an RNAP inhibitor that functions through a binding site on RNAP...
BioCentury | Sep 8, 2014
Clinical News

Xifaxan rifaximin: Additional Phase III data

...Wassermann in several European and Middle East countries. Product: Xifaxan rifaximin Business: Gastrointestinal Molecular target: Bacterial RNA polymerase (RNAP)...
BioCentury | Jul 14, 2014
Clinical News

Xifaxan rifaximin: Phase III data

...complete response letter by the end of August. Product: Xifaxan rifaximin Business: Gastrointestinal Molecular target: Bacterial RNA polymerase (RNAP)...
BioCentury | May 22, 2014
Strategy

Antibiotic team building

...his lab will pursue a project focused on optimizing new arylpropionyl-phloroglucinol-based inhibitors of bacterial RNA polymerase ( RNAP...
...The project is one of many in his lab that is investigating drug discovery against RNAP...
...studies to show that the natural product antibiotic GE23077 binds to yet another site on RNAP...
BioCentury | May 22, 2014
Distillery Therapeutics

Indication: Infectious disease

...and contact information Infectious disease Bacterial infection Bacterial RNA polymerase (RNAP) In vitro studies identified bivalent inhibitors of RNAP...
...showed that the cyclic-peptide antibiotic GE23077 inhibits bacterial growth by binding the active site of RNAP...
...site for antibacterial action. A new antibiotic was synthesized by linking GE23077 to rifamycin-which inhibits RNAP...
BioCentury | Dec 12, 2013
Distillery Therapeutics

Indication: Infectious disease

...in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection Bacterial RNA polymerase...
...anthranilic acid compounds could be useful for treating Gram-positive bacterial infections. A structural model of bacterial RNA polymerase...
BioCentury | Sep 2, 2013
Clinical News

Rifaximin soluble solid dispersion: Phase II started

...Pharmaceuticals Inc. (NASDAQ:SLXP), Raleigh, N.C. Product: Rifaximin soluble solid dispersion (SSD) Business: Hepatic Molecular target: Bacterial RNA polymerase...
BioCentury | Feb 27, 2012
Clinical News

Xifaxan rifaximin: Phase III started

...treat IBS. Salix Pharmaceuticals Ltd. (NASDAQ:SLXP), Morrisville, N.C. Product: Xifaxan rifaximin Business: Gastrointestinal Molecular target: Bacterial RNA polymerase...
BioCentury | May 10, 2010
Clinical News

Xifaxan rifaximin: Additional Phase III data

...in Italy. Salix Pharmaceuticals Ltd. (NASDAQ:SLXP), Morrisville, N.C. Product: Xifaxan rifaximin Business: Gastrointestinal Molecular target: Bacterial RNA polymerase...
Items per page:
1 - 10 of 51